Urokinase type plasminogen activator (uPA) is a highly restricted serine protease that converts the zymogen plasminogen to active plasmin, a broad-spectrum serine proteinase capable of degrading most of the major protein components of the extracellular matrix. Binding of uPA to its receptor and subsequent uPA mediated pericellular proteolysis are involved in many process including cell migration and tissue remodelling in angiogenesis, atherogenesis, tumor cell metastasis, and ovulation. High level of uPA is a poor prognostic marker for aggressive breast cancer, aggressive prostate cancer, bladder cancer and gastric cancer.

Abcam has not and does not intend to apply for the REACH Authorisation of customers’ uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.